ImmunoPrecise Antibodies Ltd. - news published 199 - readings 1.842

BACK
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership (Form 6-K)

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Man ...

Continue reading
28.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 (Form 6-K)

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. ("the Company", "ImmunoPrecise" o ...

Continue reading
28.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relati ...

Continue reading
28.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Accelerates Therapeutic Discovery with Vultr

Enabling rapid scalability and cost efficiency for breakthrough biopharma innovation ImmunoPrecise Antibodies Accelerates Therapeutic Discovery with Vultr ImmunoPrecise Antibodies (IPA) is a techbio company leveraging multi- omics modeling and advanced artificial intelligence through proprietary technologies to support the discovery and development of therapeutic antibodies. ...

Continue reading
28.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

HYFT Technology AI Bio-Native Frameworkfor Drug Discovery

+ HYFT Technology AI Bio-Native Framework for Drug Discovery Dirk Van Hyfte MD PhD CTO and Co-founder, BioStrand (IPA) VULTR + BIOSTRAND 2025 CONFIDENTIAL AND PROPRIETARY 2024 Welcome | Why AI Bio-Native Matters AI is transforming drug discovery, yet models remain limited by: HYFT's Bio-native approach addresses these issues by integrating: ✕ Homology-based methodologies (MS ...

Continue reading
20.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics (Form 6-K)

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas - ImmunoPrecise Antibodi ...

Continue reading
13.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 (Form 6-K)

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 The Company to host an earnings conference call via webcast AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the resched ...

Continue reading
12.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

The Company to host an earnings conference call via webcast AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally se ...

Continue reading
12.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

The Company to host an earnings conference call via webcast AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quar ...

Continue reading
05.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

Evolving the Intersection of Biology, Intelligence and Data for Drug Discovery.

Evolving the Intersection of Biology, Intelligence and Data for Drug Discovery. March 2025 | NASDAQ:IPA Capital structureoverview (all values in CAD unless otherwise noted) SHARE DATA (as of February 22, 2025, $ in USD) Shares Outstanding 45,765,118 Share Price USD $0.39 Market Cap USD $17,848,396 BALANCES (as of February 22, 2025) Unrestricted Cash $13.2 million FINANCIAL DAT ...

Continue reading
03.03.2025
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutio ...

Continue reading
26.02.2025